T. Rowe Price Associates
ELTX icon

T. Rowe Price Associates’s Elicio Therapeutics ELTX Stock Holding History

T. Rowe Price Associates’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42K Buy
+10,586
New +$106K ﹤0.01% 3202
2021
Q4 		– Sell
-1,270
Closed -$124K – 2998
2021
Q3 		$124K Buy
+1,270
New +$137K ﹤0.01% 2803

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates's ELTX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 10,586 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #3202 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ELTX as recently as Q3 2021.

T. Rowe Price Associates first reported a position in ELTX in Q3 2021 and has held it in 2 quarters since. The position peaked at $124K in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • T. Rowe Price Associates held 10,586 shares of Elicio Therapeutics worth $42K as of Q2 2026.
  • Elicio Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3202 holding.
  • T. Rowe Price Associates first reported a position in Elicio Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • T. Rowe Price Associates's Elicio Therapeutics position peaked at $124K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.